- Home
- PCTY vs NUVL Comparison
PCTY vs NUVL Comparison
Compare PCTY & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCTY
- NUVL
- Stock Information
- Founded
- PCTY 1997
- NUVL 2017
- Country
- PCTY United States
- NUVL United States
- Employees
- PCTY N/A
- NUVL N/A
- Industry
- PCTY Computer Software: Prepackaged Software
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- PCTY Technology
- NUVL Health Care
- Exchange
- PCTY Nasdaq
- NUVL Nasdaq
- Market Cap
- PCTY 8.5B
- NUVL 7.2B
- IPO Year
- PCTY 2014
- NUVL 2021
- Fundamental
- Price
- PCTY $142.40
- NUVL $93.00
- Analyst Decision
- PCTY Buy
- NUVL Strong Buy
- Analyst Count
- PCTY 17
- NUVL 12
- Target Price
- PCTY $209.13
- NUVL $123.33
- AVG Volume (30 Days)
- PCTY 703.8K
- NUVL 596.8K
- Earning Date
- PCTY 11-04-2025
- NUVL 10-30-2025
- Dividend Yield
- PCTY N/A
- NUVL N/A
- EPS Growth
- PCTY 2.58
- NUVL N/A
- EPS
- PCTY 4.00
- NUVL N/A
- Revenue
- PCTY $1,640,437,000.00
- NUVL N/A
- Revenue This Year
- PCTY $9.77
- NUVL N/A
- Revenue Next Year
- PCTY $8.97
- NUVL N/A
- P/E Ratio
- PCTY $35.46
- NUVL N/A
- Revenue Growth
- PCTY 13.30
- NUVL N/A
- 52 Week Low
- PCTY $135.46
- NUVL $55.54
- 52 Week High
- PCTY $223.80
- NUVL $104.90
- Technical
- Relative Strength Index (RSI)
- PCTY 37.56
- NUVL 51.51
- Support Level
- PCTY $135.46
- NUVL $89.38
- Resistance Level
- PCTY $148.74
- NUVL $95.93
- Average True Range (ATR)
- PCTY 4.67
- NUVL 5.08
- MACD
- PCTY -0.12
- NUVL -0.86
- Stochastic Oscillator
- PCTY 31.50
- NUVL 22.36
About PCTY Paylocity Holding Corporation
Founded in 1997, Paylocity is a cloud-based human capital management and payroll platform servicing midmarket customers. The company's average client size is around 150 employees. Its products help with recruiting and onboarding, payroll, time and labor, human resources, benefits, learning, and performance and compensation workflows. In fiscal 2025, the company generated over $1.5 billion in revenue across more than 41,000 customers.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.